While proven to help, primary care clinicians have been slow to use the drugs once considered only for patients with diabetes ...

AstraZeneca's SGLT2 inhibitor Farxiga has hit the mark in a phase 3 heart failure trial that brings it back into contention with its main rival Jardiance from Boehringer Ingelheim and Eli Lilly.

AstraZeneca's Farxiga reduced the risk of hospitalisation and death in people with all types of heart failure in the DELIVER trial, which could dramatically increase the population of patients ...

By Pushkala Aripaka, Bhanvi Satija and Maggie Fick LONDON, Feb 10 (Reuters) - AstraZeneca forecast steady profit growth in ...

After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030 ...

The White House has rolled out TrumpRx, a new government website that promises sharply lower prices on dozens of prescription ...

President Donald Trump last week launched a new prescription discount platform called TrumpRx, offering 43 medications at ...

A new federal prescription drug site promises to save patients money on popular drugs. Here’s what physicians should know about TrumpRx.

TrumpRx.gov is now live in California, offering discounted cash‑pay prices on 40+ meds. Here’s how it works and who benefits ...

A variety of potentially life-saving medications are available online, including Insulin Lispro, Farxiga and Tikosyn. There ...

AstraZeneca Plc’s playbook to break into the red-hot obesity market rests on improving upon existing medicines, offering competitive prices and leaning on its experience selling products in emerging ...

Chinese prosecutors have brought formal charges against AstraZeneca and its former executives following investigations into alleged illegal patient data collection and importation of drugs. | Chinese ...